Anavex Presents Positive Initial Phase 2a Study Data with ANAVEX 2-73 showing Early Evidence of Improving Cognition in Patients with Alzheimer’s Disease at AAIC 2015

NEW YORK, NY, July 22, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced initial positive cognitive data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation. Cognitive…